Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning.

Journal: Science advances
PMID:

Abstract

Cell lines and patient-derived xenografts are essential to cancer research; however, the results derived from such models often lack clinical translatability, as they do not fully recapitulate the complex cancer biology. Identifying preclinical models that sufficiently resemble the biological characteristics of clinical tumors across different cancers is critically important. Here, we developed MOBER, Multi-Origin Batch Effect Remover method, to simultaneously extract biologically meaningful embeddings while removing confounder information. Applying MOBER on 932 cancer cell lines, 434 patient-derived tumor xenografts, and 11,159 clinical tumors, we identified preclinical models with greatest transcriptional fidelity to clinical tumors and models that are transcriptionally unrepresentative of their respective clinical tumors. MOBER allows for transformation of transcriptional profiles of preclinical models to resemble the ones of clinical tumors and, therefore, can be used to improve the clinical translation of insights gained from preclinical models. MOBER is a versatile batch effect removal method applicable to diverse transcriptomic datasets, enabling integration of multiple datasets simultaneously.

Authors

  • Slavica Dimitrieva
    Disease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.
  • Rens Janssens
    NIBR, Oncology, Novartis Institutes for BioMedical Research Inc, 4056 Basel, Switzerland.
  • Gang Li
    The Centre for Cyber Resilience and Trust, Deakin University, Australia.
  • Artur Szalata
    Disease Area Oncology, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.
  • Rajaraman Gopalakrishnan
    Disease Area Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
  • Chintan Parmar
    Departments of Radiation Oncology.
  • Audrey Kauffmann
    NIBR, Oncology, Novartis Institutes for BioMedical Research Inc, 4056 Basel, Switzerland.
  • Eric Y Durand
    NIBR, Oncology, Novartis Institutes for BioMedical Research Inc, 4056 Basel, Switzerland.